1. Home
  2. SMHI vs CBIO Comparison

SMHI vs CBIO Comparison

Compare SMHI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SMHI
  • CBIO
  • Stock Information
  • Founded
  • SMHI 1989
  • CBIO 2003
  • Country
  • SMHI United States
  • CBIO United States
  • Employees
  • SMHI N/A
  • CBIO N/A
  • Industry
  • SMHI Marine Transportation
  • CBIO
  • Sector
  • SMHI Consumer Discretionary
  • CBIO
  • Exchange
  • SMHI Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • SMHI 175.6M
  • CBIO 173.5M
  • IPO Year
  • SMHI N/A
  • CBIO N/A
  • Fundamental
  • Price
  • SMHI $7.16
  • CBIO $12.68
  • Analyst Decision
  • SMHI
  • CBIO Strong Buy
  • Analyst Count
  • SMHI 0
  • CBIO 5
  • Target Price
  • SMHI N/A
  • CBIO $25.60
  • AVG Volume (30 Days)
  • SMHI 69.6K
  • CBIO 90.6K
  • Earning Date
  • SMHI 10-29-2025
  • CBIO 07-31-2025
  • Dividend Yield
  • SMHI N/A
  • CBIO N/A
  • EPS Growth
  • SMHI N/A
  • CBIO N/A
  • EPS
  • SMHI N/A
  • CBIO N/A
  • Revenue
  • SMHI $255,033,000.00
  • CBIO N/A
  • Revenue This Year
  • SMHI N/A
  • CBIO N/A
  • Revenue Next Year
  • SMHI $9.97
  • CBIO N/A
  • P/E Ratio
  • SMHI N/A
  • CBIO N/A
  • Revenue Growth
  • SMHI N/A
  • CBIO N/A
  • 52 Week Low
  • SMHI $3.63
  • CBIO $10.83
  • 52 Week High
  • SMHI $10.59
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • SMHI 65.68
  • CBIO 44.44
  • Support Level
  • SMHI $6.19
  • CBIO $12.03
  • Resistance Level
  • SMHI $7.42
  • CBIO $13.21
  • Average True Range (ATR)
  • SMHI 0.33
  • CBIO 0.81
  • MACD
  • SMHI 0.05
  • CBIO -0.09
  • Stochastic Oscillator
  • SMHI 78.61
  • CBIO 23.80

About SMHI SEACOR Marine Holdings Inc.

Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: